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Aim To investigate whether increased YKL-40 levels pos-
itively correlate with graft-vs-host disease (cGVHD) activ-
ity and severity and if YKL-40 could serve as a disease bio-
marker.
Methods This case-control study was conducted at the 
University Hospital Centre Zagreb from July 2013 to Oc-
tober 2015. 56 patients treated with hematopoietic stem 
cell transplantation (HSCT) were included: 35 patients with 
cGVHD and 21 without cGVHD. There was no difference 
between groups in age, sex, median time from transplant 
to study enrollment, intensity of conditioning, type of do-
nor, or source of stem cells. Blood samples were collected 
at study enrollment and YKL-40 levels were measured with 
ELISA. Disease activity was estimated using Clinician’s Im-
pression of Activity and Intensity of Immunosuppression 
scales and disease severity using Global National Institutes 
of Health (NIH) score.
Results YKL-40 levels were significantly higher in cGVHD 
patients than in controls (P = 0.003). The difference re-
mained significant when patients with myelofibrosis were 
excluded from the analysis (P = 0.017). YKL-40 level signifi-
cantly positively correlated with disease severity (P < 0.001; 
correlation coefficient 0.455), and activity estimated using 
Clinician’s Impression of Activity (P = 0.016; correlation co-
efficient 0.412) but not using Intensity of Immunosuppres-
sion (P = 0.085; correlation coefficient 0.296).
Conclusion YKL-40 could be considered a biomarker of 
cGVHD severity and activity. However, validation in a larg-
er group of patients is warranted, as well as longitudinal 
testing of YKL-40 levels in patients at risk of developing 
cGVHD.
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Chronic graft vs host disease (cGVHD) remains the most 
important cause of non-relapse morbidity and mortal-
ity in long-term survivors after hematopoietic stem cell 
transplantation (HSCT) (1,2) and by far its most intriguing 
complication. Although the precise immunologic mecha-
nism leading to cGVHD development still remains to be 
elucidated, there have been some recent advances in un-
derstanding the disease process and identification of po-
tential biomarkers (1-4). cGVHD is a multisystem disorder 
characterized by immune-dysregulation, resulting in im-
paired organ function, increased risk of infections, and de-
teriorated quality of life. Patients present with a variety of 
symptoms and organs involved including the skin, mouth, 
eye, gut, liver, lungs, joints, and genitourinary system (5-7). 
In the recent years the incidence of cGVHD has been in-
creasing (2), likely related to the increased donor (8) and 
recipient age (9), decreased early post-transplant mortal-
ity, use of matched unrelated donors, and peripheral blood 
stem cell grafts (10,11). Identifying biomarkers that could 
be used to predict response to treatment, assess disease 
activity, or distinguish reversible disease activity from irre-
versible damage would be of great clinical value (12). Un-
fortunately, even though a number of potential biomark-
ers have been identified, such as anti-double-strand DNA 
antibodies, adiponectin, soluble IL-2 receptor α (IL-2Rα), 
B-cell activating factor (BAFF), CXCL9, and CD13 (12-15), 
there is still no reliable marker that could be widely used 
in cGVHD patients.
Chitin, a polymer of N-acetylglucosamine, is present in 
coatings and cell walls of many organisms including bacte-
ria, fungi, nematodes, insects, and plants (16-21). Chitinas-
es, whose function is to degrade chitin, have been gener-
ally considered not to be present in mammals due to the 
absence of chitin. YKL-40, a member of the mammalian 
chitinase-like glycoproteins, is a heparin- and chitin-bind-
ing lectin without chitinase activity (22). It is expressed in 
various cell types including neutrophils (23), macrophages 
(24), bone marrow megakariocytes (25), chondrocytes and 
synovial cells (26,27), as well as in malignant cells (28). In 
normal bone marrow, YKL-40 protein is stored in the gran-
ules of the myelocytes and metamyelocytes, and released 
from fully activated cells (29). YKL-40 is also expressed by 
macrophages in vitro during the late stage of differentiation 
(29), in vivo during inflammation (30), and by peritumoral 
macrophages (31). Furthermore, YKL-40 modulates vascular 
endothelial cell morphology by promoting the formation 
of branching tubules, acts as a chemoattractant for en-
dothelial cells, stimulates their migration, and promotes 
the migration and adhesion of vascular smooth mus-
cle cells, indicating its role in angiogenesis (32). It has been 
shown to increase the growth rates of fibroblasts synergisti-
cally working with insulin-like growth factor-1 (IGF-1) (26). 
Its production is regulated by various cytokines. Studies in 
interleukin 6 (IL-6) knockout mice revealed that YKL-40 ex-
pression depended on IL-6 (33). Expression of YKL-40 mRNA 
in human monocyte is strongly stimulated by IFNγ, and in-
hibited by IL-4 and dexamethasone (34).
The physiological and biological functions of YKL-40 are 
still unclear. YKL-40 has been implicated in various inflam-
matory conditions, such as infections (35), autoimmune 
diseases (36-38), liver diseases (39,40) and malignant dis-
eases (24,25,28,41-45). Mainly due to its role in inflamma-
tion (30) and extracellular matrix remodeling (26), it has 
been investigated as a potential biomarker of several au-
toimmune conditions (36,38), as well as those that include 
fibroblast activation (40,43).
In the non-myeloablative allogeneic HSCT setting, high-
er pretransplant recipient and donor plasma YKL-40 con-
centrations suggest a role for YKL-40 as a biomarker for 
relapse and treatment-related toxicity. Recipients with pre-
transplant YKL-40 concentrations above the age-adjusted 
95th percentile (high) had higher relapse-related mortality 
and lower progression-free and overall survival. Recipients 
transplanted with donors with high YKL-40 concentrations 
had an increased probability and risk of grade 2-4 acute 
graft-vs-host disease (aGVHD) (45,46). However, none of the 
studies so far has examined whether post-transplant levels 
of YKL-40 influence the transplant outcomes or GVHD.
Based on the strong involvement of YKL-40 in inflamma-
tory processes and autoimmune disorders, particularly giv-
en that YKL-40 production depends on IL-6 secretion and 
also IFNγ stimulation, we hypothesized that its expression 
was higher in patients with cGVHD than in transplanted 
patients without cGVHD and that it positively correlated 
with disease severity and activity.
PatIeNtS aND MethoDS
Patients
This case-control study is part of a larger project entitled 
“Clinical and Biological Factors Determining Severity and 
Activity of Chronic GVHD After Allogeneic Hematopoietic 
Stem Cell Transplantation” at the University Hospital Cen-
ter Zagreb. The project included all patients who were re-
ferred to hematologist for post-transplantation follow up, 
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regardless of their age or underlying diagnosis, who con-
sented to the study participation. Excluded from participa-
tion were patients with significant medical condition or 
any other significant circumstance that could affect the 
patient’s ability to tolerate, comply, or complete the study 
and patients who according to the investigators assess-
ment had life expectancy less than 3 months. Over the 
period of July 2013 to October 2015, 76 patients treated 
with hematopoietic stem cell transplantation (HCST) were 
included in the project: 47 patients who developed cGVHD 
and 29 who did not develop cGVHD and who served as 
controls (Table 1).
For 56 patients (35 patients with cGVHD and 21 controls) 
included in the project serum samples were obtained at 
enrolment and stored. These patients were included in 
the study presented here. Prior to enrolment all partici-
pants signed the informed consent, and the study was 
approved by the University Hospital Center Zagreb Ethics 
Committee.
Data collection
Data regarding the diagnosis, time and type of transplant, 
and donor characteristics, and demographic data were col-
lected. Blood samples for measurement of YKL-40 level and 
C-reactive protein (CRP) were taken at the time of study 
enrollment. For patients with established cGVHD diagnosis 
additional data regarding the severity and activity of dis-
ease were collected using predefined forms. Disease ac-
tivity was defined by Clinician’s Impression of Activity and 
Intensity of Immunosuppression Scale. Clinician’s impres-
sion of activity was defined as: inactive, off systemic ther-
apy or topical immunosuppression; inactive, on systemic 
therapy or topical immunosuppression; active irrespective 
of the level of current therapy; and highly active irrespec-
tive of the level of current therapy (47). Intensity of immu-
nosuppression scale was defined as: none; mild = single 
agent prednisone <0.5 mg/kg/d; moderate = prednisone 
≥0.5 mg/kg/d and/or any single agent/modality; high = 2 
or more agents/modalities ± prednisone ≥0.5 mg/kg/d 
(47,48). Disease severity was defined by Global National In-
stitutes of health (NIH) scoring. Patients had mild cGVHD 
if only 1 or 2 organs (except lungs) were involved, with a 
maximum score 1 in all affected organs. Patients had mod-
erate cGVHD if at least 1 organ was involved with clinically 
significant, but not major disability (maximum score 2) or 
3 or more organs with no clinically significant functional 
impairment (maximum score 1 in all affect organs); a lung 
score 1 was classified as moderate. Patients had severe 
cGVHD if they had major impairment caused by cGVHD 
(score 3 in any organ); lung scores of 2 or 3 were classified 
as severe. Organs scored included the skin, eyes, mouth, 
gastrointestinal tract, liver, lungs, and joint/fascia. The geni-
tal area was scored only in women (49).
YKL-40 analysis
Plasma samples were prepared from EDTA (EDTA)-antico-
agulated blood taken at the time of inclusion and were 
tabLe 1. Characteristics of patients who underwent hematopoietic stem cell transplantation (hSCt) with and without chronic graft-
vs-host disease (cGVhD)
cGVhD (n = 35) Control (n = 21) P
Median age, years (range)  45 (9-60)  40 (16-59) 0.912
Sex female, n (%)  18 (51.4)  10 (47.6) 0.783
male, n (%)  17 (48.6)  11 (52.4)
Diagnosis aplastic anemia, n (%)   3 (8.6)   1 (4.8) 0.679
acute lymphoblastic leukemia, acute myeloid leukemia, n (%)  21 (60.0)  10 (47.6)
chronic lymphocytic leukemia, n (%)   1 (2.9)   2 (9.5)
chronic myeloid leukemia and myeloproliferative diseases, n (%)   6 (17.1)   6 (28.6)
lymphoma, n (%)   2 (5.7)   2 (9.5)
immunodeficiencies, n (%)   1 (2.9)   0 (0.0)
multiple myeloma, n (%)   1 (2.9)   0 (0.0)
Donor relationship related, n (%)  21 (60.0)   9 (42.9) 0.213
unrelated, n (%)  14 (40.0)  12 (57.1)
Cell source bone marrow, n (%)  15 (42.9)   8 (38.1) 0.726
peripheral cells, n (%)  20 (57.1)  13 (61.9)
Days from transplantation 
to enrollment, median 
(range)
463 (61-7853) 428 (190-1770) 0.441
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stored at -80°C until YKL-40 analysis. YKL-40 plasma con-
centration was measured using a commercially available 
ELISA kit (R&D Systems Europe, Abingdon, UK).
Statistical analysis
After testing for normality using Kolmogorov-Smirnov 
test and due to small sample size we decided to use non-
parametric tests. Categorical variables are presented as 
frequencies and corresponding percentages and quanti-
tative variables as medians and interquartile ranges. The 
differences in categorical clinical parameters between pa-
tients and controls were analyzed using Fisher exact test or 
Fisher-Freeman-Halton exact test of independence when 
the contingency table was larger than 2 × 2, while differ-
ences in quantitative variables were analyzed using Mann-
Whitney U test. Differences in YLK-40 levels between NIH 
groups were analyzed using Kruskal-Wallis test. Spearman 
correlation coefficients were calculated to assess the cor-
relation between YLK-40 levels and other clinical variables. 
P values below 0.05 were considered significant. Data anal-
ysis software system IBM SPSS Statistics, version 21.0 (IBM 
Corp., Armonk, NY, USA) was used.
ReSuLtS
Patient characteristics
Median age was 45 years (interquartile range 27-52 years) 
in the cGVHD group and 40 years (interquartile range 33-
54 years) in the control group. There were 18 women in 
cGVHD group and 9 in the control group. Graft stem cell 
source was the bone marrow in 15 (42.9%) and 8 (38.1%) 
and peripheral blood cells in 20 (57.1%) and 13 (61.9%) pa-
tients in cGVHD and control group, respectively. 17 (48.6%) 
and 8 (38.1%) patients received transplant from a related 
donor, while 18 (51.4%) and 13 (61.9%) patients received it 
from an unrelated donor in cGVHD and control group, re-
spectively (Table 1). Myeloablative conditioning was used 
in 17 (48.6%) and 8 (38.1%) patients in cGVHD and control 
group, respectively. In the cGVHD group, 4 patients had 
mild, 15 moderate, and 16 severe symptoms as assessed 
by Global NIH score.
CGVHD and control patient groups were comparable ac-
cording to age, sex, time from transplantation to enroll-
ment, type of disease, cell source, donor relationship, 
intensity of conditioning, total body irradiation use in con-
ditioning, and myelofibrosis as primary disease (Table 1).
Plasma YKL-40 concentration in cGVhD and control 
group
YKL-40 levels in cGVHD patients were significantly high-
er than in the control group (median 707 pg/mL [inter-
quartile range 525-1054] vs 314 pg/mL [interquartile range 
169-635]; P = 0.003) (Figure 1A). Since YKL-40 is known to 
be increased in patients suffering from myelofibrosis, we 
excluded the data of all the patients with a history of my-
elofibrosis from the analysis (3 patients, [8.6%] in cGVHD 
FIGuRe 1. (A) Significantly higher YKL-40 serum concentration in chronic graft-vs-host disease (cGVhD) patients compared to control 
group. (B) the difference in YKL-40 serum concentration between cGVhD and control group remained significant after patients suf-
fering from myelofibrosis were excluded from the analysis. 6 patients were excluded, 3 from each group.
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group and 3 patients, [14.3%] in control group). After these 
patients were excluded, the concentration of YKL-40 was 
still significantly higher in cGVHD group than in the control 
group (median 633.5 pg/mL [range 71-1689] vs 351.5 pg/
mL [range 105-2790]; P = 0.017) (Figure 1B).
Correlation of YKL-40 concentration and disease activity 
and severity
YKL-40 levels significantly positively correlated with Clini-
cian’s Impression of Activity (P = 0.016; correlation coef-
ficient 0.412) and Global NIH score (P < 0.001; correlation 
coefficient 0.455) (Figure 2), but not with Intensity of Im-
munosuppression (P = 0.085; correlation coefficient 0.296). 
Since YKL-40 protein is involved in inflammation process, 
we tested its correlation with the CRP level, to establish if 
the YKL-40 level was increased due to persistent chronic 
inflammation not noticed by the examining physician and 
found no significant correlation (P = 0.581) (Table 2).
DISCuSSIoN
Our study shows that the level of circulating YKL-40 is sig-
nificantly higher in patients with cGVHD than in transplant-
ed patients without cGVHD and correlates with disease se-
verity and activity, as measured by Global NIH score and 
Clinicians Impression of Activity, respectively.
Although the exact role of glycoprotein YKL-40 in chronic 
inflammation is still not elucidated, YKL-40 concentration 
was found to be increased in 54% of patients with clinically 
active rheumatoid arthritis (RA). In patients in whom RA be-
came inactive serum YKL-40 concentration decreased after 
12 months, but increased in patients with RA flare (50). Fur-
thermore, it has been shown that the level of circulating 
YKL-40 depends on IL–6 secretion, stimulated by IFNγ (45) 
and inhibited by IL-4 (33,34,51). Also, IL-6 and IFNγ have 
been shown to increase during GVHD development (52) 
and IL-6 is crucial for Th17 pathway (53), while production 
of IL-4 has been shown to be decreased in cGVHD patients 
(54). This could in part explain why YKL-40 is increased in 
active cGVHD reaction.
Furthermore, it was previously shown that patients with 
myelofibrosis had highly elevated levels of circulating YKL-
40 in comparison to healthy controls (43). However, in our 
study the difference in plasma YKL-40 concentration be-
tween cGVHD group and control group remained signifi-
cant after patients with myelofibrosis were excluded. The 
cause of elevated YKL-40 in myelofibrosis patients has not 
been found, but increased bone turnover and pronounced 
chronic inflammation have been implicated (43). Both pro-
cesses are aborted after successful HSCT, and therefore, the 
fact that patient once had myelofibrosis should not influ-
ence the post-transplant level of YKL-40 protein. The effect 
of donor and recipient pre-transplant level of circulating 
YKL-40 on transplant outcomes (ie, relapse-related mor-
tality, progression-free survival, overall survival, and acute 
GVHD incidence) has been reported, but post-transplant 
levels have not been investigated (45,46).
Even though our study distinctly shows concentration of 
YKL-40 to be significantly higher in patients with cGVHD 
in comparison to controls, it has several limitations. It is a 
single center study with a limited number of included pa-
tients. Albeit there was no significant difference between 
groups in time from transplant to sampling, there was a 
considerably wide range among patients within each 
group (range for cGVHD group was 61 to 7853 days, 
control 190 to 1770 days). This is because patients 
FIGuRe 2. YKL-40 serum concentration was positively corre-
lated with global National Institutes of health score.
tabLe 2. univariate analysis of YKL-40 serum concentration 
and chronic graft-vs-host disease (cGVhD) activity and severity 
measurements
Correlation 
coefficient
 
P
Clinicians impression of activity 0.412 0.016
Intensity of immunosuppression 0.296 0.085
Global National Institutes of Health score 0.455 <0.001
National Institutes of Health average score 0.208 0.231
C reactive protein 0.097 0.581
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were included at various points after having been diag-
nosed with cGVHD and at various stages of disease. Even 
though it would be preferable if the study included only 
newly diagnosed patients to limit the influence of disease 
advancement and/or therapy, the patients included in this 
study were clinically very well characterized according to 
2005 NIH Consensus criteria.
In our study YKL-40 levels positively correlated with Glob-
al NIH score, a measure of disease severity, and Clinician’s 
Impression of Activity, a measure of disease activity. We 
agree that data shown here do not prove YKL-40 protein 
to be a valid biomarker, but they certainly indicate that it 
is a strong new candidate. In our opinion, YKL-40 needs to 
be explored as a potential biomarker on a larger number of 
cGVHD patients. In addition, a longitudinal study of post-
transplant patients, with serial, predefined time points is 
needed to validate these results, establish the dynamics of 
YKL-40 expression, and determine its role in evaluating the 
response to treatment.
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